A recent study reported that the administration of the TLR4 agonist Lipopolysaccharid (LPS) could augment the tumor-reactivity of adoptively transferred pmel-1 CD8+ T cells in mice with established B16.F10 tumors (127). This evidence concerns the gene CD8A and neoplasm.